Inify Laboratories provides cancer diagnostics through ultramodern laboratory services within pathology. It uses a fully digital, standardized and AI- supported workflow to optimize quality and response times, initially within prostate. The concept is scalable and can be extended to other diagnoses. The service includes the whole chain of sample handling: from logistics, to sample preparation, to reporting by a pathologist from either Inify Laboratories or the customer’s organization. The report is assisted by our own AI, proven in clinical studies to have world-leading accuracy. The complete workflow is supported by a tailor-made process control system. The company, based in Sweden, became independent in 2022 through a spin-off from ContextVision, with 40 years of experience within digital imaging for medical applications. It is listed on Euronext Growth Oslo under the ticker INIFY.
| Website | http://www.inify.com |
| Revenue | $592.7 million |
| Employees | 49 (30 on RocketReach) |
| Founded | 2022 |
| Address | Scheeles Väg 3, Solna, Stockholm County 17165, SE |
| Phone | +46 8 26 73 30 |
| Industry | Hospitals and Health Care |
| Keywords | Cancer Screening, Cancer Diagnostics, Pathology Laboratory, Clinical Diagnostics, Digital Pathology, Laboratory Services, Medical Diagnostics, Healthcare Analytics, Healthcare Technology, Precision Oncology, Oncology Diagnostics, Diagnostic Testing, Quality Control Lab, Medical Laboratory, Pathology Testing |
| Competitors | Thermo Fisher Scientific, Illumina, Agilent Technologies, Bio-Rad Laboratories, QIAGEN, Merck Group, NanoString Technologies, Inc., Roche, SOPHiA GENETICS, PacBio +45 more (view full list) |
Looking for a particular Inify Laboratories employee's phone or email?
The Inify Laboratories annual revenue was $592.7 million in 2026.
Fredrik Palm is the CEO of Inify Laboratories.
30 people are employed at Inify Laboratories.
Inify Laboratories is based in Solna, Stockholm County.